Eric Shen Email & Phone Number

Boston, MA, US

Boston, Massachusetts, US

The T1D Fund is a venture philanthropy fund accelerating life-changing solutions to cure, prevent, and ultimately treat T1D. It’s the first scaled, mission-driven venture philanthropy fund focused on equity investments in partnership with additional sources of capital, including venture capital, corporations, and foundations. Launched in December 2016, our.

Boutique consulting firm focusing on early stage biotech startups helping provide solutions in the realm of corporate development (strategy & operations, business development, investor engagement, etc.)

Boston, Massachusetts, US

At Kojin Therapeutics, we have pioneered a fundamentally new way of looking at biology that unlocks enormous potential for drug discovery. Our expertise resides in translating our deep biological insight into cell state and ferroptosis biology to small-molecule therapeutics which creates novel ways of treating “untreatable” cancers. Founded by world-class.

An evergreen family-associated fund that makes early stage investments in Biotech, Digital Health, AI, and Material Sciences.

Cambridge, Massachusetts, US

Ohana Biosciences is pioneering a new approach to revolutionize reproductive health, using its novel platform of sperm-based technologies in order to enhance fertilization in patients undergoing ART, gain insights to reduce pregnancy complications and genetic disease in infants, and create a long-lasting non-hormonal contraceptive for both men and women.

Cambridge, Massachusetts, US

Collaborating with multiple functional leads to aggregate major inflection points, assumptions, risks, and interdependencies and update key corporate strategic documents. Maintaining an ongoing foundational scientific knowledge base by facilitating weekly R&D meetings where scientific concepts & experimental data were discussed and translated into.

Creating business processes surrounding outbound discovery product concepts in multiple indications by managing input from product, engineering, clinical, regulatory, and commercial teams. Spearheading ad-hoc strategic projects regarding drug delivery, sensing, algorithms, and discovery stage opportunities. Identifying and evaluating new innovative.

Provided deliverables in the form of business cases, competitive intelligence, and research reports to support inbound and outbound deal processes. Aided in conducting a comprehensive portfolio strategy examining 40+ disease areas for potential commercial deployment. Crafted 30+ digital therapeutic concepts within a variety of indications based on analysis.

Coordinated process with C-suite executives to prepare updated materials for Board of Directors on a quarterly basis. Participated in generating materials for the FDA additional information request leading to approval of the first ever digital therapeutic claiming specific therapeutic benefit, reSET® for SUD. Extracted data key to securing Pear's second.